COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib
(INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis
(either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or
Post-Essential Thrombocythemia Myelofibrosis (PET-MF).